Back to Search
Start Over
Alzamend seeks FDA approval for a trial for an improved version of the most commonly used treatment for bipolar disorder
- Source :
- Plus Company Updates. August 30, 2023
- Publication Year :
- 2023
-
Abstract
- Alzamend Neuro Inc ALZN has submitted a New Drug Application (IND) to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder. Lithium is a commonly [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.763278243